Glycopyrronium bromide (Glycopyrronii bromidum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

M-holinoblokatory

Included in the formulation
  • Sybri® Brizhaler®
    capsulespowder d / inhal. 
    Novartis Pharma AG     Switzerland
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    R.03.B.B.06   Glycopyrronium bromide

    Pharmacodynamics:

    Inhalation preparation of prolonged action. Selectively and competitively blocks M1-3 muscarinic receptors, removes the bronchoconstrictive effect of acetylcholine on the smooth muscle cells of the respiratory tract and thereby causes a persistent bronchodilating effect.

    Pharmacokinetics:

    After inhalation, it is absorbed into the systemic circulation. Bioavailability is about 40%. The maximum concentration in the blood plasma is reached after 5 minutes. The connection with plasma proteins is 38-41%.

    The maximum therapeutic effect develops 5 minutes after application. Metabolism in the liver.

    The half-life is 33-57 hours. Elimination by the kidneys.

    Indications:It is used for the purpose of maintenance therapy for violations of bronchial patency in patients with chronic obstructive pulmonary disease.

    ICD-10

    X.J40-J47.J42   Chronic bronchitis, unspecified

    X.J40-J47.J43   Emphysema

    X.J40-J47.J44   Other chronic obstructive pulmonary disease

    Contraindications:Simultaneous reception with other M-holinoblokatorami, individual intolerance, children's age to 18 years.

    Carefully:Closed-angle glaucoma, urinary retention, renal failure, myocardial infarction, arrhythmia, lengthening interval QT, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Inhalation, 50 mcg once a day at the same time.

    The highest daily dose: 50 mcg.

    The highest single dose: 50 mcg.

    Side effects:

    Central and peripheral nervous system: headache, insomnia, rarely - hypoesthesia, asthenia.

    Respiratory system: rhinitis, nasopharyngitis, throat irritation, epistaxis, productive cough.

    The cardiovascular system: rarely - a feeling of heartbeat, ventricular fibrillation.

    Digestive system: dry mouth, vomiting, gastroenteritis, rarely - caries.

    Musculoskeletal system: myalgia, rarely - pain in the muscles of the chest.

    Dermatological reactions: rarely - a rash.

    Urinary system: urinary tract infections, rarely - urinary retention, cystitis.

    Allergic reactions.

    Overdose:Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:Clinically significant interactions are not described.

    Special instructions:

    The drug is not used to stop acute bronchospasm.

    Instructions
    Up